Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;81(10):1123-7.
doi: 10.1136/jnnp.2010.205757. Epub 2010 May 16.

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study

T T Seppälä  1 , S-K Herukka, T Hänninen, S Tervo, M Hallikainen, H Soininen, T Pirttilä
Affiliations

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study

T T Seppälä et al. J Neurol Neurosurg Psychiatry. 2010 Oct.

Abstract

Background: Single measurements of plasma Aβ are not useful in the diagnostics of Alzheimer's disease (AD). However, changes in plasma Aβ levels during repeated testing may be helpful in the prediction and evaluation of progression of the incipient AD or mild cognitive impairment.

Objective: To examine the relation of baseline and serial plasma Aβ levels to cognitive change in follow-up.

Methods: 269 subjects (52 cognitively impaired and 217 controls) from a population-based cohort were clinically followed up from 3 to 6 years. Serial plasma samples were available from 70 subjects who were followed up for 3 years and 43 subjects followed for 6 years. The plasma Aβ levels were measured using ELISA.

Results: Subjects who declined cognitively during the follow-up had lower levels of plasma Aβ42 at the baseline. Plasma Aβ42 and the Aβ42/Aβ40 ratio decreased (-2.4 pg/ml for Aβ42 in 6 years) in those who declined in follow-up, whereas Aβ42 and the Aβ42/Aβ40 ratio increased in the subjects who remained cognitively stable or improved in follow-up. Subjects using acetylsalicylic acid, dipyridamole, antidiabetic or anticoagulant drugs as well as subjects with coronary heart disease had higher levels of Aβ40.

Conclusions: Low or decreasing plasma Aβ42 during the follow-up is associated with cognitive decline. Serial measurement of plasma Aβ42 may be useful in the detection of the subjects who are at risk for cognitive decline.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Figures

Figure 1
Figure 1
Formation of the study population.
See this image and copyright information in PMC

References

    1. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994;53:438–7 - PubMed
    1. Chen M, Inestrosa NC, Ross GS, et al. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995;213:96–103 - PubMed
    1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741–66 - PubMed
    1. Gravina SA, Ho L, Long KE, et al. Amyloid beta Protein (Abeta) in Alzheimer's Disease Brain. J Biol Chem 1995;270:7013–16 - PubMed
    1. Iwatsubo T, Mann DM, Odaka A, et al. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 1995;37:294–99 - PubMed

Publication types